Status:
COMPLETED
ThuLEP vs. HoLEP vs. Monopolar Enucleation in Management of BPH
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University
Conditions:
Prostatic Hyperplasia, Benign
Prostate Adenoma
Eligibility:
MALE
50-90 years
Phase:
NA
Brief Summary
Today, endoscopic enucleation of the prostate (EEP) has been recognized a method of choice for treatment of benign prostatic hyperplasia (BPH) of any size, including large-sized glands (\>80 cc). The ...
Detailed Description
HoLEP and ThuLEP or EEP have been approved by the current guidelines of the European Association of Urology for use in men with substantially enlarged prostates (\>80 ml) as first-line therapy \[1\]. ...
Eligibility Criteria
Inclusion
- IPSS\>20;
- maximum urinary flow rate\< 10ml\\s (Qmax);
- ineffective alfa-blockers therapy.
Exclusion
- histologically verified prostate cancer;
- history of prostatic surgery;
- urethral strictures;
- bladder stones;
- chronic urinary retention and cystostomy.
Key Trial Info
Start Date :
January 15 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2017
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT03230721
Start Date
January 15 2015
End Date
July 21 2017
Last Update
July 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.